The DOI matches its Crossref record; 138 of the 140 references it cites were found in a registry or an index.
Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy?
Open accessAbstract
Tumor immune microenvironment (TIME), a tumor-derived immune component, is proven to be closely related to the development, metastasis, and recurrence of tumors. Gut microbiota and its fermented-metabolites short-chain fatty acids (SCFAs) play a critical role in maintaining the immune homeostasis of gastrointestinal tumors. Consisting mainly of acetate, propionate, and butyrate, SCFAs can interact with G protein-coupled receptors 43 of T helper 1 cell or restrain histone deacetylases (HDACs) of cytotoxic T lymphocytes to exert immunotherapy effects. Studies have shed light on SCFAs can mediate the differentiation and function of regulatory T cells, as well as cytokine production in TIME. Additionally, SCFAs can alter epigenetic modification of CD8+ T cells by inhibiting HDACs to participate in the immune response process. In gastrointestinal tumors, the abundance of SCFAs and their producing bacteria is significantly reduced. Direct supplementation of dietary fiber and probiotics, or fecal microbiota transplantation to change the structure of gut microbiota can both increase the level of SCFAs and inhibit tumor development. The mechanism by which SCFAs modulate the progression of gastrointestinal tumors has been elucidated in this review, aiming to provide prospects for the development of novel immunotherapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the biological plausibility of this diet-microbiota-immune axis rests on the idea that microbial breakdown of dietary fiber and other prebiotic foods results in the production of immunomodulatory metabolites.13,137,138”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [137]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00277 · Cited by 3,820 · cited 1×
“As key regulators of immune function, SCFAs can regulate T cells, B cells, macrophages, and other immune cells (3).”
BackgroundCarbohydrate quality and human health: a series of systematic reviews and meta-analyses
Reynolds, A., Mann, J., Cummings, J., Winter, N., Mete, E., & Te Morenga, L. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31809-9 · Cited by 1,630
Park, J., Kim, M., Kang, S. G., Jannasch, A. H., Cooper, B., Patterson, J., & Kim, C. H. (2015) · Mucosal Immunology · doi:10.1038/mi.2014.44 · Cited by 1,307 · cited 1×
“Whatever the polarization conditions, SCFAs promoted interleukin (IL)-10 expression, but could only facilitate the production of IL-17 or interferon-g (IFN-g) under specific environments (54).”
BackgroundReck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00174 · Cited by 1,159 · cited 1×
“The treatment scheme based on the immune system, such as immune checkpoint inhibitors (ICIs), has been applied in the clinic (6, 7).”
MethodCD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052 · cited 1×
“T cells are vital cells in TIME, especially decreased infiltration or dysfunction of T cells leads to poor clinical results in many cancer treatments (53).”
BackgroundYang, W., Yu, T., Huang, X., Bilotta, A. J., Xu, L., Lu, Y., Sun, J., Pan, F., Zhou, J., Zhang, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18262-6 · Cited by 1,042 · cited 1×
“Meanwhile, butyrate-promoted HIF-1a combination with the HRE of the IL-22 promoter involved histone acetylation (Figure 2) (57).”
BackgroundWild Mouse Gut Microbiota Promotes Host Fitness and Improves Disease Resistance
Rosshart, S. P., Vassallo, B. G., Angeletti, D., Hutchinson, D. S., Morgan, A. P., Takeda, K., Hickman, H. D., McCulloch, J. A., Badger, J. H., Ajami, N. J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.016 · Cited by 862 · cited 1×
“Treatment of dextran sulfate sodium or azoxymethane can induce CRC in laboratory mice, and FMT from wild mice to experimental mice could improve this process (128).”
BackgroundLuu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24331-1 · Cited by 771 · cited 4×
“Pentanoate Clostridioides difficile; Megasphaera massiliensis (48) Increased the function of mTOR as a central cellular metabolic sensor and inhibited class I HDAC activity to enhance the anti-tumor activity of CTLs and CAR T cells (9), same as butyrate;”
BackgroundInfluentialHe, Y., Fu, L., Li, Y., Wang, W., Gong, M., Zhang, J., Dong, X., Huang, J., Wang, Q., Mackay, C. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.002 · Cited by 729 · cited 2×
“In addition, the level of butyrate was high in the serum of responder patients compared to nonresponder patients in CRC (61).”
Background
Research works printed but not linked: 1
- Kang, 2023, Butyrate ameliorates colorectal cancer through regulating intestinal microecological disorders, Anticancer Drugs, 34, 10.1097/cad.0000000000001413 · DOI
Cited by
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential
Xiao, Y.-L., Gong, Y., Qi, Y.-J., Shao, Z.-M., & Jiang, Y.-Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01771-x · Cited by 202
“285 Metabolic and epigenetic reprogramming enables pentanoate and butyrate to enhance the effectiveness of cancer immunotherapy by boosting the antitumor activity of antigen-speci fi c cytotoxic T lymphocytes and ROR1-targeting chimeric antigen receptor (CAR)-”
BackgroundA Comprehensive Review of the Triangular Relationship among Diet–Gut Microbiota–Inflammation
Randeni, N., Bordiga, M., & Xu, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179366 · Cited by 127
Peng, K., Xiao, S., Xia, S., Li, C.-L., Yu, H., & Yu, Q. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c04456 · Cited by 117
Melanoma and microbiota: Current understanding and future directions
Routy, B., Jackson, T., Mählmann, L., Baumgartner, C. K., Blaser, M., Byrd, A., Corvaia, N., Couts, K., Davar, D., Derosa, L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.003 · Cited by 89
Microbiome as a biomarker and therapeutic target in pancreatic cancer
Pourali, G., Kazemi, D., Chadeganipour, A. S., Arastonejad, M., Kashani, S. N., Pourali, R., Maftooh, M., Akbarzade, H., Fiuji, H., Hassanian, S. M., et al. (2024) · BMC Microbiology · doi:10.1186/s12866-023-03166-4 · Cited by 78
Metadata
- Authors
- Dong, Y., Zhang, K., Wei, J., Ding, Y., Wang, X., Hou, H., Wu, J., Liu, T., Wang, B., & Cao, H.
- Affiliations
- Tianjin Medical University General Hospital (CN)
- Corresponding author
- Cao, Hailong
- ORCID
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-04-14
- Volume
- 14
- Pages
- 1158200-1158200
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC10140337
- OpenAlex
- W4365516124
- Cited by
- 107
- References
- 140
- Citations by year
- 2026: 36 · 2025: 41 · 2024: 25 · 2023: 5
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82070545, 82100574, 81970477)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- gut microbiota, short-chain fatty acids, gastrointestinal cancer, tumor immune microenvironment, butyrate, histone deacetylase, GPR43, regulatory T cells, CD8+ T cells, epigenetic modifications, dietary fiber, probiotics, fecal microbiota transplantation, immunotherapy
- MeSH terms
- Gastrointestinal Microbiome, Butyrates, Fatty Acids, Volatile, Gastrointestinal Neoplasms, Humans, CD8-Positive T-Lymphocytes, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy? https://app.cochat.ai/papers/10.3389/fimmu.2023.1158200
- The paper
- Dong, Y., Zhang, K., Wei, J., Ding, Y., Wang, X., Hou, H., Wu, J., Liu, T., Wang, B., & Cao, H. (2023). Gut microbiota-derived short-chain fatty acids regulate gastrointestinal tumor immunity: a novel therapeutic strategy? Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1158200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.